Compare Goodyear Tire & Rubber Co (GT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Sanofi SA — how do they compare? Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 69.5× Goodyear Tire & Rubber Co's market cap, and Sanofi SA pays a 6.01% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Sanofi SA for 94 Days on average.
| GT | SNY | |
|---|---|---|
Market Cap | $1.37B | $95.18B |
Volume | 9,470,773 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $52.34 |
52-Week Low | $4.66 | $39.51 |
Typical Hold Time | 57 Days | 94 Days |
Enterprise Value | $8.72B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The Goodyear Tire & Rubber Company (GT) trades at $4.75, down 1.28% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 4.69 and P/B of 0.48, but faces fundamental challenges including negative net income margin of -14.37% and ROE of -63.93%. Recent earnings showed mixed results with Q2 2026 beating expectations despite a loss, while the company executes a restructuring strategy focusing on premium EV tires.
GT presents a high-risk opportunity with significant upside potential given the $8.00 consensus price target, but investors face substantial execution risks amid ongoing restructuring, declining revenues, and persistent losses. The bearish technicals and mixed analyst sentiment (34.62% buy rating) suggest cautious optimism dependent on successful turnaround execution and margin improvement.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
